Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on March 10, 2023. The filing addresses the recent closure of Silicon Valley Bank (SVB) and the appointment of the Federal Deposit Insurance Corporation as receiver.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. The report focuses exclusively on the company's exposure to the SVB event.
Material Changes and Exposure
Phio Pharmaceuticals confirmed it does not hold cash deposits or securities at Silicon Valley Bank. Consequently, the Company has no financial exposure in connection with SVB's closure. No material changes to the Company's financial position were reported as a result of this event.
Management Commentary and Risks
Management issued a statement clarifying the Company's lack of involvement with SVB to address investor concerns regarding potential liquidity risks associated with the bank's failure. No other risks, contingencies, or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the Company's cash holdings and banking relationships in subsequent quarterly reports (10-Q) or annual reports (10-K).
- Confirm that no other banking partners faced similar regulatory actions during this period.
- Review the Company's overall liquidity position in the most recent audited financial statements.